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Guidelines for Vancomycin
Use
To the Editor—In the new guidelines
for vancomycin monitoring published in
August 2009 in Clinical Infectious Diseases,
Rybak et al [1] state that “continuous in-
fusion regimens are unlikely to substan-
tially improve patient outcome when com-
pared to intermittent dosing” (p 326). In
the original text [2] accompanying these
guidelines, the authors cite 4 studies by
James et al (1996) [3], Lacy et al (2000)
[4], and Wysocki et al (1995 [5] and 2001
[6]) to support their claim.
The first study, of which Dr Rybak is
final author, was pharmacologic in nature
and did not assess clinical outcome. It
concluded that continuous infusion and
conventional dosing vancomycin therapy
“demonstrated equivalent pharmacody-
namic activities” [3, p 696], although the
serum bactericidal titer in the continuous-
dosing group remained 11:8 for 100% of
the time and that in the conventional-dos-
ing group remained 11:8 for only 60% of
the time. This study was very small, com-
prising only 10 patients, and had a cross-
over period of only 2 days.
To our surprise, we found that the sec-
ond study in question has been flatly mis-
represented. Rybak and colleagues assert
that Lacy et al “found virtually no differ-
ence in activity as measured by bactericidal
titers between continuous and intermit-
tent infusions” [2, p 87]. In fact, the study
of Lacy and colleagues did not investigate
continuous infusion of vancomycin—it
only compared vancomycin given as 1 g
once a day with vancomycin given as 1 g
twice a day.
Furthermore, the authors cite 2 studies
by Wysocki et al. In the first (1995) [5],
13 patients were prospectively treated with
vancomycin by continuous infusion and
matched with historical control subjects.
Infection-related mortality was 23% low-
er in the continuous-infusion group, al-
though the small number of patients as
well as confounding factors ultimately pre-
cluded the drawing of “definitive conclu-
sions” (p 354). The authors followed this
pilot study with a randomized prospective
trial in 2001 [6] that compared continu-
ous to intermittent vancomycin infusion
among 119 patients with severe staphy-
lococcal infections. Indeed, microbiologic
outcomes, clinical outcomes, and safety
were similar in both groups. This study
was limited, however, by its small sample
size and short period of follow-up (10
days).
On a theoretical and pharmacologic
level, as demonstrated in Dr Rybak’s study
[3], the time-dependent nature of van-
comycin supports its administration by
continuous infusion. On a clinical lev-
el, there is currently not enough evidence
to claim that treatment with continuous-
infusion vancomycin produces a supe-
rior outcome; additionally, larger trials
are needed. However, there is clearly not
enough evidence to suggest the oppo-
site—absence of evidence is not evidence
of absence.
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Olympics in the Tropics
and Infectious Diseases
To the Editor—The International
Olympic Committee has chosen the Bra-
zilian city of Rio de Janeiro to host the
2016 Olympic Games, making it the first
South American venue in Olympic his-
tory. The Olympic Games are a very pop-
ular but also vulnerable global event and
thus intrinsically raise the expectations of
the international community on all as-
pects of preparedness, including public
health. Communicable diseases have not
been a significant cause of health events
during recent mass gatherings for major
international sporting events. Despite this,
